Gossamer Bio Q3 Loss Narrows to $48M; Cash Runs Only Into Q1 2027
GOSS sits 22% above its 52-week low of $8.29 on light trading volume (0.4× avg).
Summary
Gossamer Bio posted a $48.1 million Q3 loss and ended September with $51.2 million in cash, enough to fund operations only into Q1 2027. The $125 million second closing of its private placement hinges on FDA accepting the seralutinib NDA for filing in 2026.
Key Events · Earnings and Guidance · GOSS
-
Q3 Loss of $48.1 Million
Net loss was $48.1 million for the three months ended September 30, 2026, versus $48.2 million a year earlier; nine-month loss narrowed to $77.8 million from $123.1 million.
-
Cash Only Funds Operations Into Q1 2027
Cash and cash equivalents were $51.2 million at September 30, 2026, and management states existing cash is not sufficient to fund operating plans for at least one year, raising substantial doubt about going concern.
-
Revenue Inflated by Chiesi Termination
Q3 revenue of $38.4 million included $37.1 million of contract liabilities released as revenue when the Chiesi collaboration terminated on July 23, 2026; no further revenue is expected under that agreement.
-
$125 Million Second Closing Hinges on FDA
The August 2026 private placement's second closing for roughly $125 million requires FDA acceptance of the seralutinib NDA for filing in 2026; if it does not occur by December 31, 2026, that tranche and the FDA Approval Warrants terminate.
Analysis · GOSS · Life Sciences
The headline $48.1 million quarterly loss flatters the underlying operations: $37.1 million of Chiesi deferred revenue was pulled forward as revenue when the collaboration was terminated on July 23, 2026, and the $43.8 million debt-extinguishment gain from the June exchange sits in the nine-month numbers. Strip those out and the company is still burning cash, with $51.2 million on hand and management saying that only funds operations into the first quarter of 2027. The $84.5 million warrant liability is a non-cash mark-to-market on the August private placement warrants, not new dilution or a cash obligation. The real swing factor is the $125 million second closing of that placement, which is contingent on the FDA accepting the seralutinib NDA for filing in 2026; if it does not happen by December 31, 2026, that tranche and the FDA Approval Warrants terminate.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 47.7% of the 1624 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GOSS was trading at $10.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $68.9M. The 52-week trading range was $8.29 to $309.60. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.